YUE YU

Dr. YUE YU

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
SCSvetlana A. Chechetka
Svetlana A. Chechetka
YYYUE YU
YUE YU
XZXu Zhen
Xu Zhen
MPManojit Pramanik
Manojit Pramanik
KPKanyi Pu
Kanyi Pu
EMEijiro Miyako
Eijiro Miyako
Room temperature liquid metals (LMs) represent a class of emerging multifunctional materials with attractive novel properties. Here, we show that photopolymerized LMs present a unique nanoscale capsule structure characterized by high water dispersibility and low toxicity. We also demonstrate that the LM nanocapsule generates heat and reactive oxygen species under biologically neutral near-infrared (NIR) laser irradiation. Concomitantly, NIR laser exposure induces a transformation in LM shape, destruction of the nanocapsules, contactless controlled release of the loaded drugs, optical manipulations of a microfluidic blood vessel model and spatiotemporal targeted marking for X-ray-enhanced imaging in biological organs and a living mouse. By exploiting the physicochemical properties of LMs, we achieve effective cancer cell elimination and control of intercellular calcium ion flux. In addition, LMs display a photoacoustic effect in living animals during NIR laser treatment, making this system a powerful tool for bioimaging.

1 May 2018 in iScience
Verified
Journal Article
Open access
YYYUE YU
YUE YU
EMEijiro Miyako
Eijiro Miyako
As emergent multifunctional materials, room temperature liquid metals (LMs) display many unique properties. Here we show that applying an external alternating magnetic field (AMF) to an LM induces various physical phenomena, such as exothermic behavior, controlled locomotion, electromagnetic levitation, and transformations of the LMs between different morphologies and configurations, in a non-contact manner. Additional interesting therapeutic bioengineering applications of LMs demonstrated herein include in vitro and in vivo effective cancer magnetic hyperthermia via wireless AMF, remote manipulation of a pill-shaped microdevice based on an LM/hydrogel composite, and spatiotemporal controlled release of drug molecules from the microdevice. Overall, as an innovative therapeutic bioengineering technology, this platform and the described performance traits of LMs enable the development of biocompatible smart devices with a wide range of dynamic components that can be wirelessly controlled in a manner that solves issues related to the powering of devices and biocompatibility.

1 May 2013 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
RGRan Gao
Ran Gao
YYYUE YU
YUE YU
AIAtsushi Inoue
Atsushi Inoue
NWNashi Widodo
Nashi Widodo
Sunil KaulSunil Kaul
Sunil Kaul
RWRenu Wadhwa
Renu Wadhwa
Cancer is a leading cause of death and still awaits effective therapies. Rapid industrialization has contributed to increase in incidence of cancer. One of the reasons why most of the cancers fail therapy is due to their metastatic property. Hence identification of factors leading to metastasis is highly important to design effective and novel anti-cancer therapeutics. In our earlier study (Inoue, A., Sawata, S. Y., Taira, K., and Wadhwa, R. (2007) Loss-of-function screening by randomized intracellular antibodies: identification of hnRNP-K as a potential target for metastasis. Proc. Natl. Acad. Sci. U.S.A. 104, 8983–8988), we had reported that the involvement of heterogeneous nuclear ribonucleoprotein K (hnRNP-K) in metastasis. Here, we established hnRNP-K-overexpressing and -underexpressing derivative cell lines and examined their proliferation and metastatic properties in vitro and in vivo. Whereas hnRNP-K compromised cells showed delayed tumor growth, its overexpression resulted in enhanced malignancy and metastasis. Molecular basis of the hnRNP-K induced malignant and metastatic phenotypes was dissected by cDNA microarray and pathway analyses. We found that the hnRNP-K regulates extracellular matrix, cell motility, and angiogenesis pathways. Involvement of the selected genes (Cck, Mmp-3, Ptgs2, and Ctgf) and pathways was validated by gene-specific expression analysis. Our results demonstrated that the hnRNP-K is a potential target for metastasis therapy.

1 February 2017 in Chem
Verified
Journal Article
Closed access
SCSvetlana A. Chechetka
Svetlana A. Chechetka
YYYUE YU
YUE YU
MTMasayoshi Tange
Masayoshi Tange
EMEijiro Miyako
Eijiro Miyako

2 October 2017 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
YYYUE YU
YUE YU
EMEijiro Miyako
Eijiro Miyako

17 August 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
YYYUE YU
YUE YU
XYXi Yang
Xi Yang
SRSheethal Reghu
Sheethal Reghu
Sunil KaulSunil Kaul
Sunil Kaul
RWRenu Wadhwa
Renu Wadhwa
EMEijiro Miyako
Eijiro Miyako
Strategies for eradicating cancer stem cells (CSCs) are urgently required because CSCs are resistant to anticancer drugs and cause treatment failure, relapse and metastasis. Here, we show that photoactive functional nanocarbon complexes exhibit unique characteristics, such as homogeneous particle morphology, high water dispersibility, powerful photothermal conversion, rapid photoresponsivity and excellent photothermal stability. In addition, the present biologically permeable second near-infrared (NIR-II) light-induced nanocomplexes photo-thermally trigger calcium influx into target cells overexpressing the transient receptor potential vanilloid family type 2 (TRPV2). This combination of nanomaterial design and genetic engineering effectively eliminates cancer cells and suppresses stemness of cancer cells in vitro and in vivo. Finally, in molecular analyses of mechanisms, we show that inhibition of cancer stemness involves calcium-mediated dysregulation of the Wnt/β-catenin signalling pathway. The present technological concept may lead to innovative therapies to address the global issue of refractory cancers.